VHIO’s Scientific Coordination Area has consolidated itself as a Unit to support VHIO’s Direction, Management, and research groups for the development of research proposals and programs, monitoring and follow up. We also provide support to our various Task Forces, that strengthen and promote multidisciplinary connectivity and spur joint research programs with other oncology teams at the Vall d’Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus.
Our managerial responsibilities include both financial and scientific support, as well as the implementation of institutional actions to various areas including education, ethics & regulatory issues, scientific dissemination, consortia and coordinated research. These cover competitive grant application processes, dissemination of national and international funding opportunities for our researchers, assessment of the preparation and writing of competitive project proposals, as well as the monitoring and coordination of awarded research projects.
We aim to optimize opportunities for the internationalization of groups through a personalized plan for VHIO groups, centralize ideas from taskforces and match selected research priorities with competitive calls, as well as support highly innovative technological project proposals to increase VHIO’s success rate in terms of Innovative Medicines Initiative (IMI), and H2020 and Horizon Europe framework approved projects as coordinators and partners through the proactive search and evaluation of opportunities, as well as potentiate our area’s organizational structure and optimize our project management processes.
Identify and promote new research opportunities involving academic and industry partners.
Write, coordinate and manage scientific proposals.
Manage, monitor and follow up institutional programs.
Promote intramural research through education, networking and driving force.
In 2020, we maintained a good track record with a success rate of 29%, out of 205 grant (competitive) applications.
This year, our Area managed more than 9.2 million EUR obtained from competitive funds.
Our research support to VHIO groups has been recognized through our co-authorship of three publications - see our Paper pick.
We supported the preparation and management of our Scientific Advisory Board (SAB) virtual meeting.
We have provided support to our Scientific Direction through the management of scientific data, documents and actions required for the elaboration and development of research proposals and projects at VHIO. In addition, this year we received funding through a MINECO European Networks and Management grant to support the internationalization of our activities, expand our personnel, and organize educational and dissemination activities to improve our researchers' knowledge surrounding European funding programs.
Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J, Massard C, Opdam FL, Schlenk R, Vernieri C, Garralda E, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium, Calvo F, Fröhling S, Eggermont A, Apolone G, Voest EE, Caldas C, Tabernero J, Ernberg I, Rodon J, Lehtiö J. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nat Med. 2020 Jul;26(7):992-994.
Cedrés S, Ponce-Aix S, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Gómez-Abecia S, Zucchiatti AC, Sansano I, Enguita AB, Miquel JM, Viaplana C, Dienstmann R, Paz-Ares L, Felip E. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. Clin Transl Oncol. 2020 Aug;22(8):1390-1398.
van de Haar J, Hoes LR, Coles CE, Seamon K, Fröhling S, Jäger D, Valenza F, de Braud F, De Petris L, Bergh J, Ernberg I, Besse B, Barlesi F, Garralda E, Piris-Giménez A, Baumann M, Apolone G, Soria JC, Tabernero J, Caldas C, Voest EE. Caring for patients with cancer in the COVID-19 era. Nat Med. 2020 May;26(5):665-671.
ACADEMIC CRO (VHIO - aCRO)
VHIO's Academic Contract Research Organization (VHIO-aCRO), has extensive experience in conducting sponsored trials and investigator-initiated trials. We offer a complete package of start-to-end management services required to perform clinical trials and studies. Thanks to our multidisciplinary team, we can operate as a full service CRO in clinical studies from phase I to IV studies.
We also offer guidance to all researchers and sponsors on how to achieve the best experimental design and logistical advice in order to maximize their resources. With a team of 6 professionals, our Unit provides medical writing support, full regulatory activities, monitoring, project management, e-CRF creation, statistics, drug management, insurance management, and pharmacovigilance activities.
We seek to expand our Unit’s structure with a clinical project manager and a CRA to be able to even more effectively manage current and future clinical trials, optimize CRO digital tools to allow for working remotely, as well as continue to bring out the best in each team member to enhance our newly created Facility.
Clinical project management support to awarded R&D projects (European/Pharma funded), academic Oncology Clinical Trials led by our Medical Oncologists and Clinical Investigators at VHIO and the Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Barcelona Hospital Campus.
Academic CRO for Investigator initiated trials.
Academic CRO for pharmacy sponsored trials, when VHIO is involved in the development of the trial.
In 2020 our academic CRO successfully managed a number of major projects including COMBAT, TOPIC, IRONMAN, MONEO, among others. Most of these are led the Vall d’Hebron University Hospital (HUVH) oncology teams, at the Medical Oncology Department headed by Josep Tabernero, VHIO’s Director.
During 2020, we successfully met the regulatory requirements of all of our trials (first submissions and amendments).
Our CRA team were able to monitor more than 150 patients in several hospitals throughout Spain.
We managed clinical trials drug requirements in more than 25 national hospitals.
We have also evidenced sufficient benefits to cover CRO activities for non-funded academic trials.